Cellulite, leg wellness and forskolin

Forskolin, found in the Indian coleus plant (also known as coleus forskohlii, coleus barbatus, plectranthus barbatus) is probably the most potent natural lipolytic chemical available (stimulates fat release), and also a vasodilator. Forskolin is therefore of great importance as an active ingredient in anti-cellulitecontouring and under-eye creams.

 

Forskolin cellulite creams, by Celluence®

The forskolin used for the Celluence® cellulite creams is of the highest quality and of >95% purity, i.e. it comprises more than 95% active molecule, in a natural, super-fast absorption matrix (due to it's very expensive price, forskolin is not widely used in anti-cellulite creams, and when it is used, it is quite often either of low purity or in minute concentrations). We are extremely proud to feature a high quality, highly purified forskolin in our formulations, together with multiple other natural active ingredients, for maximum synergy and effectiveness. No other cellulite creams offer ALL the important anti-cellulite / leg wellness ingredients, in one package (learn how our creams differ from any other cellulite formulation).

 

 

Forskolin

All Papers & articles

 

(Disclaimer: please note that the information and the research presented on this page is for informational purposes only and does not constitute efficacy claims for the Celluence® creams, neither does it constitute or aim to replace medical advice)

 

 

STIMULATION OF CAMP ACCUMULATION AND LIPOLYSIS IN HAMSTER ADIPOCYTES WITH FORSKOLIN.

  • Journal: American journal of physiology
  • Abstract: This study compares the effects of forskolin and isoproterenol on lipolysis and adenosine 3',5'-cyclic monophosphate (cAMP) accumulation in hamster white adipocytes. Rates of lipolysis in forskolin-stimulated cells were equivalent to those in cells incubated with isoproterenol, but cAMP levels were more than 10-fold greater in the presence of forskolin. The stimulatory effects of forskolin were partially inhibited by N6-phenylisopropyl adenosine but not by 2',5'-dideoxyadenosine. In other experiments, cells were exposed to forskolin in combination with either isoproterenol or adenosine deaminase. A concentration of forskolin that caused only a small increase in lipolysis was used. When isoproterenol or adenosine deaminase were added withforskolin, lipolysis increased dramatically, but cAMP content either did not change, as occurred with isoproterenol, or increased only slightly with adenosine deaminase. Isoproterenol potentiation of forskolin's lipolytic action persisted in the absence of extracellular K+, even though the lipolytic response to isoproterenol alone was absent in K+-free media. These data demonstrate that the lipolytic responses of adipose tissue are more complex than are responses simply in proportion to cellular concentration of cAMP. Such complexity could arise if lipolytic regulatory factors other than cAMP existed or if cAMP and protein kinase were functionally segregated within adipocytes.
  • Link: http://ajpcell.physiology.org/content/246/1/C63.full.pdf

 

QUANTITATIVE DIFFERENCES IN THE CYCLIC AMP-LIPOLYSIS RELATIONSHIPS FOR ISOPROTERENOL AND FORSKOLIN.

  • Journal: Journal of pharmacology and experimental therapeutics
  • Abstract: The relationships between cyclic AMP (cAMP) levels and glycerol release (lipolysis) were determined for isoproterenol and forskolin under varied conditions in the isolated fat cell of the rat. Prevention of the inhibitory action of endogenous adenosine [by adenosine deaminase (100 mU/ml) or theophylline (3.3 X 10(-4) M)] resulted in increased levels of cAMP and increased rates of lipolysis with forskolin. However, the relationship between cAMP levels and rates of lipolysis remained the same under all conditions. N6-phenylisopropyladenosine (PIA; an analog of adenosine) abolished the increase in cAMP level produced by isoproterenol (10(-7) M) or forskolin (10(-6) M) and the lipolytic response to forskolin. However, PIA failed to inhibit completely the lipolytic response to isoproterenol. Dose-response curves to isoproterenol were determined in the presence and absence of adenosine deaminase. PIA (10(-6) M) inhibited the increase in cAMP levels under both conditions. PIA also inhibited the lipolytic responses that were associated with increases in cAMP levels, i.e., high concentrations of isoproterenol alone and isoproterenol with adenosine deaminase. A plot of cAMP levels against corresponding rates of lipolysis for all conditions agreed with previous observations that the relationship for isoproterenol differs from that for forskolin. At any concentration of cAMP the corresponding lipolytic response was greater for isoproterenol than for forskolin. The possibility of a cAMP-independent lipolytic response was discussed.
  • Link: http://jpet.aspetjournals.org/content/244/3/852.abstract

 

INSULIN SENSITIZES BETA-AGONIST AND FORSKOLIN-STIMULATED LIPOLYSIS TO INHIBITION BY 2',5'-DIDEOXYADENOSINE.

  • American journal of physiology
  • In isolated rat adipocytes incubated in the absence of insulin, 2',5'-dideoxyadenosine blocked the increase in total adenosine 3',5'-cyclic monophosphate (cAMP) accumulation due to beta 1- or beta 3-catecholamine agonists and forskolin without affecting their stimulation of lipolysis. The inhibition of cAMP accumulation by 2',5'-dideoxyadenosine was not reflected in the total cytosolic cAMP-dependent protein kinase A activity, suggesting that the inhibition of cAMP occurred in cellular compartments distinct from those involved in the regulation of bulk protein kinase A activity. However, there was a good correlation between effects of lipolytic agents on cytosolic protein kinase A activity in fat cell extracts and lipolysis. Furthermore, it was possible to see an inhibition of the increase due to beta-agonists in cAMP accumulation, protein kinase A activity, and lipolysis by 2',5'-dideoxyadenosine in the presence of insulin. These data suggest that the readily measurable accumulation of cAMP seen with catecholamines in the absence of insulin is in a compartment separate from that involved in protein kinase A activation.
  • http://ajpcell.physiology.org/content/270/2/C562

 

EFFECT OF COLEUS FORSKOHLII EXTRACT ON CAFETERIA DIET-INDUCED OBESITY IN RATS.

  • Journal: Pharmacognosy Research
  • Abstract: Background: Obesity is a metabolic disorder that can lead to adverse metabolic effects on blood pressure, cholesterol, triglycerides and insulin resistance and also increases the risk of coronary heart disease, ischemic stroke and type 2 diabetes mellitus. This study was designed to determine the effect of Coleus forskohlii on obesity and associated metabolic changes in rats fed with cafeteria diet. Objective: The aim of this study was to evaluate antiobesogenic and metabolic benefits of C. forskohlii in cafeteria diet induced obesity rat model. Materials and Methods: Rats were randomly divided into five groups of six animals in each group and as follows: Normal pellet diet group; cafeteria diet group; cafeteria diet followed by 50 mg/kg/d Coleus forskohlii extract (CFE), 100 mg/kg/d CFE and 45 mg/kg/d orlistat groups, respectively. Indicators of obesity such as food intake, body weight and alteration in serum lipid profiles were studied. Results: Feeding of cafeteria diet induced obesity in rats. Administration of CFE significantly halted increase in food intake and weight gain associated with cafeteria diet. Development of dyslipidemia was also significantly inhibited. Conclusion: The observed effects validate that supplementation of CFE with cafeteria diet could curb the appetite and mitigate the development of dyslipidemia.

 

BODY COMPOSITION AND HORMONAL ADAPTATIONS ASSOCIATED WITH FORSKOLIN CONSUMPTION IN OVERWEIGHT AND OBESE MEN

  • Journal: Obesity
  • Abstract: Objective: This study examined the effect of forskolin on body composition, testosterone, metabolic rate, and blood pressure in overweight and obese (BMI ≥ 26 kg/m2) men. Research Methods and Procedure: Thirty subjects (forskolin, n = 15; placebo, n = 15) were studied in a randomized, double-blind, placebo-controlled study for 12 weeks. Results: Forskolin was shown to elicit favorable changes in body composition by significantly decreasing body fat percentage (BF%) and fat mass (FM) as determined by DXA compared with the placebo group (p ≤ 0.05). Additionally, forskolin administration resulted in a change in bone mass for the 12-week trial compared with the placebo group (p ≤ 0.05). There was a trend toward a significant increase for lean body mass in the forskolin group compared with the placebo group (p = 0.097). Serum free testosterone levels were significantly increased in the forskolin group compared with the placebo group (p ≤ 0.05). The actual change in serum total testosterone concentration was not significantly different among groups, but it increased 16.77 ± 33.77% in the forskolin group compared with a decrease of 1.08 ± 18.35% in the placebo group. Discussion: Oral ingestion of forskolin (250 mg of 10% forskolin extract twice a day) for a 12-week period was shown to favorably alter body composition while concurrently increasing bone mass and serum free testosterone levels in overweight and obese men. The results indicate that forskolin is a possible therapeutic agent for the management and treatment of obesity.
  • Link: http://onlinelibrary.wiley.com/doi/10.1038/oby.2005.162/abstract